143 related articles for article (PubMed ID: 34028091)
1. Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
Tanveer F; Anwar MF; Siraj B; Zarina S
Biotechnol Appl Biochem; 2022 Jun; 69(3):1226-1237. PubMed ID: 34028091
[TBL] [Abstract][Full Text] [Related]
2. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
4. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
Asadollahi-Baboli M
Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
[TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
[TBL] [Abstract][Full Text] [Related]
6. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
9. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
[TBL] [Abstract][Full Text] [Related]
12. Homology models of the mutated EGFR and their response towards quinazoline analogues.
Kotra S; Madala KK; Jamil K
J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
[TBL] [Abstract][Full Text] [Related]
13. Differential Protein Expression in Response to Varlitinib Treatment in Oral Cancer Cell Line: an In Vitro Therapeutic Approach.
Tanveer F; Ilyas A; Syed B; Hashim Z; Ahmed A; Zarina S
Appl Biochem Biotechnol; 2024 Apr; 196(4):2110-2121. PubMed ID: 37470935
[TBL] [Abstract][Full Text] [Related]
14. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
[TBL] [Abstract][Full Text] [Related]
15. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
16. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
17. QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.
Chauhan JS; Dhanda SK; Singla D; ; Agarwal SM; Raghava GP
PLoS One; 2014; 9(7):e101079. PubMed ID: 24992720
[TBL] [Abstract][Full Text] [Related]
18. Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR.
Almalki FA; Shawky AM; Abdalla AN; Gouda AM
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770832
[TBL] [Abstract][Full Text] [Related]
19. Identification of oxazolo[4,5-g]quinazolin-2(1H)-one Derivatives as EGFR Inhibitors for Cancer Prevention.
Senthil R; Meenakshi Sundaram KK; Bupesh G; Usha S; Saravanan KM
Asian Pac J Cancer Prev; 2022 May; 23(5):1687-1697. PubMed ID: 35633554
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and therapy of oral squamous cell carcinoma.
Konkimalla VB; Suhas VL; Chandra NR; Gebhart E; Efferth T
Expert Rev Anticancer Ther; 2007 Mar; 7(3):317-29. PubMed ID: 17338652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
